top of page

Constantinos Zamboglou

Medical Director

Konstantinos Zamboglou, PhD, MHBA studied medicine in Freiburg, Germany until 2013. In this period, he completed his doctoral thesis at the laboratory of Prof. Aktories with the grade summa cum laude. He was resident in the Department of Radiation Oncology at the University of Freiburg in Germany. 


In 2019 he obtained his board licence and in 2020 his postdoctoral lecture qualification. 


From 2019-2020 he worked as senior consultant, where he was responsible for the treatment of patients suffering from genito-urethral cancer. 


In 2021 he also became the section head of the department of interventional radiotherapy. Since 2022 he is the deputy medical director at the German Oncology Center in Limassol. 


He published over 100 research articles in renown and peer-reviewed journals and in 2020 he received the “Herman-Holthusen” Award of the German Society of Radiation Oncology. 


Since 2021 he is an invited member of the German prostate cancer expert panel and since 2023, he is a member of the ESTRO focus group for genito-urethral cancer. 


For his research he received funding for over 8 million € focusing on state-of-the-art clinical trials and implementation of innovative health-technology for patient-centred care.

dct-VhrachimisAl.jpg
Education

  • 09 / 2004 – 07 / 2006 - Movie Director School, ANT1 Movie School Athens, Greece, Degree “Television Director”, grade point average: B

  • 09 / 2006 – 08 / 2008 - Medical School, Semmelweis University Budapest, Hungary, Medical preliminary examination (Physikum), grade point average: A

  • 10 / 2008 – 05 / 2013 - Medical School, Albert-Ludwigs-Universität Freiburg, Germany, State examination in medicine, grade point average: A

  • 02/ 2009 – 02/2012 - Institute of Pharamcology and Toxicology I, Albert-Ludwigs- Universität Freiburg, Germany, Doctoral thesis, grade: summa cum laude

  • 05 / 2018 - Basic and advanced course in German drug law and GCP, Clinical Trials Unit, Medical Center - University of Freiburg

  • 01 / 2019 - Board certification: Radiotherapy and Radiation Oncology

  • 03 / 2020 - Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Habilitation (Postdoctoral lecture qualification)

  • 09 / 21 – 08 / 23 - MHBA, Friedrich Alexander University, Nuernberg, Germany

  • 07 / 2022 - Completion of ISO 9001:2015 training, Nicosia, Cyprus

Professional Career

  • 09 / 2013 – 01 / 2019 - Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Residency.                                              

  • 07 / 2017 – 07 / 2020 - Bertha-Ottenstein programme, Medical Center University of Freiburg, Germany, Clinician Scientist.

  • Since 06 / 2019 - Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Consultant.

  • 01 / 2021 – 12 / 2022 - Bertha-Ottenstein programme, Medical Center University of Freiburg, Germany, Advanced Clinician Scientist.

  • 01 / 2021 – 12 / 2021- Head of the section “Interventional Radiation Oncology”,Medical Center University of Freiburg, Department of Radiation Oncology, Germany.

  • Since 01 / 2022 - Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Prostate cancer research group leader.

  • Since 01 / 2022 - German Oncology Center, Limassol, Cyprus, Vice Medical Director.

Professional Memberships and Distinctions

  • 2010: Sanofi-Aventis poster price, Annual meeting of the German Society of Pharmacology and Toxicology 2010, Mainz, Germany.  

  • 2017: Poster price, Annual meeting of the German Society of Radiation Oncology (DEGRO) 2017, Berlin, Germany.

  • 2019: Poster price, Uro-Oncological Symposium 2019, Magdeburg, Germany.

  • 2020: Invited member of the German expert panel for prostate cancer of the German Society of Radiation Oncology (DEGRO)

  • 2020 : Herman-Holthusen Award, German Society of Radiation Oncology (DEGRO).

  • 2021: Invited member of the ESTRO-ACROP guideline committee for prostate cancer.

  • 2021: Best Abstract, EMUC congress 2021, Athens, Greece.

  • 2023: Annual ARO study price for the HypoFocal-SBRT study from the German Cancer Foundation

  • 2023: Invited member of the ESTRO focus group “Urology”

Publications (10 most important as first or last author)

  1. Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer. Zamboglou C. et al., JAMA NO. 2023 May.

  2. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. Zamboglou C. et al., Int J Radiat Oncol Biol Phys. 2022 Jun.

  3. PSMA-PET- and MRI-Based Focal Dose Escalated Radiation Therapy of Primary Prostate Cancer: Planned Safety Analysis of a Nonrandomized 2-Armed Phase 2 Trial (ARO2020-01). Zamboglou C. et al., Int J Radiat Oncol Biol Phys. 2022 Apr.

  4. Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies. Spohn S, ..., Zamboglou C., Theranostics. 2021 Jun.

  5. Intraprostatic Tumour Segmentation on PSMA-PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. Kostyszyn D, …, Zamboglou C., J Nucl Med. 2020 Oct.

  6. Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Zamboglou C. et al. Radiother Oncol. 2019 Dec.

  7. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Zamboglou C. et al., Theranostics. 2019 Apr.

  8. Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis Schmidt-Hegemann N, …, Zamboglou C., J Nucl Med. 2019 Feb.

  9. Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Zamboglou C. et al., Theranostics. 2017 Jan.

  10. (68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison. Zamboglou C. et al., Theranostics. 2016 Jun.


bottom of page